ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 856

A Pathogenic Role for the Gut Microbiota in Murine Antiphospholipid Syndrome and Lupus

Silvio M. Vieira1, Andrew Yu1, Michael Hiltesperger1, Odelya E. Pagovich1, Eleni Tiniakou1, William Ruff2, John Sterpka1 and Martin Kriegel2,3, 1Yale School of Medicine, New Haven, CT, 2Immunobiology, Yale School of Medicine, New Haven, CT, 3Medicine, Section of Rheumatology, Yale School of Medicine, New Haven, CT

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Animal models, Antibiotics, antiphospholipid and microbiome, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: The etiology of lupus-associated antiphospholipid syndrome (APS) is unknown but microbial triggers have been implicated in transient antiphospholipid antibody production in both mice and humans. We hypothesize that a constant trigger of autoreactivity lies within the gut microbiome and tested if persistent reactivity to β2-glycoprotein I (β2GPI) and mortality in the spontaneous (NZWxBXSB)F1 model of lupus-associated APS are sustained by specific members of the gut microbiota.

Methods: (NZWxBXSB)F1 hybrid male mice were treated orally with combined or single antibiotics (vancomycin, metronidazole, neomycin and ampicillin) targeting different microbial community structures starting at 6 weeks of age. Female TLR7 transgenic C57BL/6 mice were similarly treated with broad-spectrum antibiotics. Sera, urine and fecal pellets were collected longitudinally and analysed for anti-β2GPI titers, proteinuria from lupus nephritis and eubacterial 16S rDNA load by real-time PCR. H&E slides were prepared from tissues for histologic analysis. Splenocyte proliferation was assessed by [3H]-thymidine incorporation.

Results: Not only broad-spectrum antibiotics but also vancomycin or ampicillin alone lowered anti-β2GPI antibodies at 4 months of age (n=5 each; p=0.014) and protected mice from deaths due to coronary microthrombi, pulmonary emboli or strokes (n=5 each; p=0.005). Proliferation of splenocytes to the autoantigen (using recombinant β2GPI) was diminished compared to anti-CD3-induced proliferation (n=8 each; p=0.0012). Proteinuria due to lupus nephritis was also suppressed in microbiota-depleted mice (n=8 each; p=0.026). Furthermore, mortality from systemic lupus-like disease was significantly reduced in lupus-prone TLR7 transgenic C57BL/6 mice treated with antibiotics (n=9-10 each; p=0.0154).

Conclusion: Vancomycin-sensitive gut commensals are necessary for anti-β2GPI-antibody-induced thrombembolic deaths. Broad-spectrum antibiotics selectively reduced T cell proliferation to β2GPI but not anti-CD3, suggesting antigen-specific effects of the gut microbiota. These results support that gram-positive members of the gut microbiota are fundamentally involved in the pathogenesis of APS. The gut microbiota modulate also lupus pathogenesis in two spontaneous models, suggesting that not only APS but also SLE is dependent on the gut microbial community composition we are currently defining to identify novel biomarkers and treatment targets.


Disclosure:

S. M. Vieira,
None;

A. Yu,
None;

M. Hiltesperger,
None;

O. E. Pagovich,
None;

E. Tiniakou,
None;

W. Ruff,
None;

J. Sterpka,
None;

M. Kriegel,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-pathogenic-role-for-the-gut-microbiota-in-murine-antiphospholipid-syndrome-and-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology